Get the Stockscreener App
155.22
1.70%
-2.68
After Hours:
155.22
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Cardinal Health Inc stock is traded at $155.22, with a volume of 3.11M.
It is down -1.70% in the last 24 hours and down -7.61% over the past month.
Cardinal Health is one of three leading pharmaceutical wholesalers in the US, engaged in sourcing and distributing of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. Cardinal, Cencora, and McKesson hold well over 90% of the US pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
See More
Previous Close:
$157.90
Open:
$157.55
24h Volume:
3.11M
Relative Volume:
1.43
Market Cap:
$37.05B
Revenue:
$222.29B
Net Income/Loss:
$1.56B
P/E Ratio:
24.22
EPS:
6.41
Net Cash Flow:
$2.44B
1W Performance:
-1.93%
1M Performance:
-7.61%
6M Performance:
+25.52%
1Y Performance:
+53.94%
1-Day Range:
$152.59
$158.73
1-Week Range:
$152.59
$159.25
52-Week Range:
$96.05
$168.44
Cardinal Health Inc Stock (CAH) Company Profile
Name
Cardinal Health Inc
Sector
Industry
Phone
(614) 757-3033
Address
7000 CARDINAL PLACE, DUBLIN, OH
Compare CAH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CAH
Cardinal Health Inc
|
155.22 | 37.69B | 222.29B | 1.56B | 2.44B | 6.41 |
|
MCK
Mckesson Corporation
|
693.54 | 89.30B | 359.05B | 3.30B | 5.23B | 25.83 |
|
COR
Cencora Inc
|
286.08 | 56.56B | 310.23B | 1.69B | 3.58B | 8.62 |
|
HSIC
Henry Schein Inc
|
67.65 | 8.70B | 12.50B | 314.00M | 421.00M | 2.44 |
|
AHG
Akso Health Group Adr
|
1.699 | 662.04M | 2.22M | -5.63M | -1.68M | -0.24 |
Cardinal Health Inc Stock (CAH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-03-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-05-25 | Upgrade | Jefferies | Hold → Buy |
| Jan-08-25 | Upgrade | TD Cowen | Hold → Buy |
| Jan-07-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Jan-06-25 | Upgrade | BofA Securities | Neutral → Buy |
| Dec-13-24 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Dec-04-24 | Resumed | Mizuho | Outperform |
| Feb-26-24 | Initiated | Leerink Partners | Outperform |
| Feb-09-24 | Upgrade | Argus | Hold → Buy |
| Jan-03-24 | Initiated | Barclays | Overweight |
| Dec-14-23 | Initiated | Wells Fargo | Underweight |
| Jul-10-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-31-23 | Initiated | Citigroup | Neutral |
| Feb-03-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Nov-04-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-22-22 | Resumed | Morgan Stanley | Overweight |
| May-26-22 | Downgrade | Barclays | Overweight → Equal Weight |
| May-18-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Apr-12-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-01-22 | Resumed | Credit Suisse | Neutral |
| Aug-06-21 | Downgrade | Deutsche Bank | Buy → Hold |
| Aug-05-21 | Downgrade | BofA Securities | Buy → Underperform |
| May-10-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-08-21 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Nov-02-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Sep-25-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Jul-20-20 | Upgrade | Guggenheim | Neutral → Buy |
| May-15-20 | Upgrade | UBS | Neutral → Buy |
| Apr-23-20 | Resumed | Credit Suisse | Neutral |
| Mar-20-20 | Upgrade | BofA/Merrill | Underperform → Buy |
| Feb-12-20 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-07-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-16-19 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-12-19 | Initiated | Deutsche Bank | Hold |
| Aug-27-19 | Downgrade | Argus | Buy → Hold |
| Aug-20-19 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-18-19 | Initiated | Guggenheim | Neutral |
| Jan-17-19 | Initiated | UBS | Neutral |
| Nov-16-18 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Apr-24-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Apr-02-18 | Upgrade | Argus | Hold → Buy |
| Mar-08-18 | Initiated | Barclays | Equal Weight |
| Feb-27-18 | Resumed | BofA/Merrill | Underperform |
| Jan-05-18 | Initiated | Evercore ISI | In-line |
View All
Cardinal Health Inc Stock (CAH) Latest News
When is Cardinal Health Inc. stock expected to show significant growthMarket Forecast Alerts To Watch Now - jammulinksnews.com
What makes Cardinal Health Inc. stock price move sharplyEntry Signal Updates For Fast Growth - jammulinksnews.com
Should Value Investors Buy Cardinal Health (CAH) Stock? - Yahoo Finance
Cardinal Health Foundation aims to improve prescription recycling, medication availability - AOL.com
Cardinal Health Foundation expands Equity Rx to increase access to prescription medications, bringing total investment to $5M – Company AnnouncementFT.com - Financial Times
Why Cardinal Health Inc. stock attracts strong analyst attentionDaily Momentum Screener With Alerts Launched - beatles.ru
Cardinal Health Inc. Recovery Likely Here’s What Data ShowsStep-by-Step Stock Investment Guide Gains Popularity - metal.it
Published on: 2025-07-29 13:14:51 - metal.it
Is it the right time to buy Cardinal Health Inc. stockGet timely alerts on market opportunities - jammulinksnews.com
Is Cardinal Health Inc. stock overvalued or undervaluedBuild wealth with long-term growth strategies - jammulinksnews.com
What catalysts could drive Cardinal Health Inc. stock higher in 2025Smart Portfolio Ideas For Fast Growth - jammulinksnews.com
Skin Biopsy Market Set to Witness Significant Growth by 2033 | - openPR.com
What are the latest earnings results for Cardinal Health Inc.Turn volatility into profit opportunities - jammulinksnews.com
Cell and Gene Therapy Third-Party Logistics Market Forecast and Company Analysis Report 2025-2033 Featuring Cencora, Cardinal Health, McKesson, EVERSANA, Knipper Health, Arvato, DHL, and Kuehne+Nagel - Yahoo Finance
Here's Why We Think Cardinal Health (NYSE:CAH) Might Deserve Your Attention Today - simplywall.st
What is Cardinal Health Inc. company’s growth strategyMaximize your returns with expert insights - jammulinksnews.com
What institutional investors are buying Cardinal Health Inc. stockStay ahead with advanced stock screening tools - jammulinksnews.com
How volatile is Cardinal Health Inc. stock compared to the marketBeginner Investor Review Backed By Experts - jammulinksnews.com
Should I hold or sell Cardinal Health Inc. stock in 2025Capitalize on emerging market opportunities - jammulinksnews.com
How does Cardinal Health Inc. compare to its industry peersUnlock your portfolio’s hidden potential - jammulinksnews.com
What are analysts’ price targets for Cardinal Health Inc. in the next 12 monthsFree Investment Portfolio Suggestions - jammulinksnews.com
Cardinal Health Earnings Preview: What to Expect - MSN
Is Cardinal Health Inc. a growth stock or a value stockFree Smart Trading Workshop - jammulinksnews.com
How many analysts rate Cardinal Health Inc. as a “Buy”Achieve explosive financial results today - jammulinksnews.com
What are Cardinal Health Inc. company’s key revenue driversBuild a balanced portfolio for long-term success - jammulinksnews.com
Cardinal Health (CAH) Beat the Market in 2025 with Solid Healthcare Momentum - MSN
Is Cardinal Health Inc. a good long term investmentExponential wealth increase - PrintWeekIndia
What analysts say about Cardinal Health Inc. stockSkyrocketing profit margins - PrintWeekIndia
Universal Health to Report Q2 Earnings: What Do the Key Estimates Say? - TradingView
Investors Will Want Cardinal Health's (NYSE:CAH) Growth In ROCE To Persist - Yahoo Finance
What drives Cardinal Health Inc. stock priceBreakthrough profits - Autocar Professional
Are Medical Stocks Lagging Cardinal Health (CAH) This Year? - Yahoo Finance
Cardinal Health Set to Announce Q4 Earnings with Promising Growth ProspectsNews and Statistics - IndexBox
Cardinal Health Earnings Preview: What To Expect - Barchart.com
Cardinal Health Inc. Stock Analysis and ForecastStrong return on assets - jammulinksnews.com
Nitrile Gloves Market Future Business Opportunities 2025-2032 | Cardinal Health, Medline Industries - openPR.com
Cardinal Health Inc. Slips to 489th in Trading Volume Ranking Despite Strategic Investments and Strong Earnings - AInvest
Cardinal Health raises FY25 earnings outlook on investor day - MSN
Cardinal Health Stock (CAH) Opinions on Upcoming Q4 Financial Results - Quiver Quantitative
Cardinal Health's Q3 2025 Success: CEO Jason Hollar's Strategic OverhaulNews and Statistics - IndexBox
Cardinal Health's Earnings Soar 260% After CEO's Turnaround Strategy - AInvest
After earnings fell by $300 million, Cardinal Health’s CEO went ‘ruthless’ to turn it around—and he says workers backed him because ‘people want to win’ - Yahoo Finance
Cardinal Health Inc Stock (CAH) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.96%
2.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):